2024-10-07 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company specializing in the development and commercialization of innovative therapies in various areas, including immunology, oncology, neurology, and eye care.

**1. Performance Analysis:**

* **Cumulative Return:** ABBV has delivered a cumulative return of 152.53% compared to the S&P 500 (VOO) return of 133.14%. 
* **Performance Gap:** ABBV has outperformed the S&P 500 by 19.39%. This performance gap currently sits at the 60.63% percentile of its historical range, indicating that ABBV has performed above average relative to the S&P 500 over the observed period.

**2. Recent Price Action:**

* **Closing Price:** $194.29
* **5-day Moving Average:** $196.20
* **20-day Moving Average:** $194.72
* **60-day Moving Average:** $189.80

The current price is slightly below the 5-day and 20-day moving averages, indicating a slight short-term downtrend. However, it's above the 60-day moving average, suggesting a longer-term uptrend.

**3. Technical Indicators:**

* **RSI:** 45.85 - The RSI is currently in the neutral zone, suggesting that ABBV is neither overbought nor oversold.
* **PPO:** -0.06 - The PPO is negative, indicating a slight bearish trend.
* **Delta_Previous_Relative_Divergence:** -11.18 - The recent 20-day relative divergence is negative, indicating a potential short-term downward pressure on the stock.
* **Expected Return:** 0.99% - This indicates a potential maximum 5-year expected return over the S&P 500, suggesting positive growth potential.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV consistently beat analysts' earnings expectations in recent quarters. The latest earnings report for Q2 2024 showed an EPS of $2.65, surpassing the expected $2.57. This positive trend suggests strong fundamental performance and a positive outlook.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Recent market outlook for ABBV is mixed, with some analysts suggesting a positive outlook due to the strong earnings performance, while others remain cautious due to potential competitive pressures and uncertainties related to key drugs' patent expirations.
* **Analyst Opinions:** Analyst opinions on ABBV are generally positive, with most rating it as a "buy" or "hold." They highlight the company's strong track record of innovation and its position in a growing market.
* **Performance Highlights:** ABBV has been facing challenges related to patent expirations for some of its key drugs, impacting revenue growth. However, the company is actively investing in R&D to maintain its pipeline of innovative therapies and diversify its revenue streams.

**6. Overall Analysis:**

ABBV has exhibited solid performance exceeding the S&P 500, with recent earnings exceeding expectations. The stock appears to be in a slight short-term downtrend but maintains a longer-term uptrend. Technical indicators suggest neutrality, with potential short-term downward pressure. While patent expirations present challenges, the company's commitment to R&D and strong performance in recent quarters indicate a positive long-term outlook.

**7. Conclusion:**

ABBV presents an attractive investment opportunity for investors seeking exposure to the pharmaceutical sector. Its consistent performance, positive outlook, and strong track record of innovation make it a promising stock for long-term growth. However, investors should monitor the ongoing patent expirations and potential competitive challenges closely before making any investment decisions. 
